| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 47.9MM | - |
| Operating Income | -19.3MM | -66% |
| Operating Expenses | 67.2MM | +8% |
| Net Income | -14.4MM | -73% |
| R&D | 53MM | +10% |
| G&A | 14.2MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact of cancer, head straight to the 5 Counties with the Highest Cancer Rates in the US. Confronting Cancer: Global Impact and Trends in […]
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET. To access the May 2 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeuti
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to discuss drug discovery and clinical translation strategies for STAT3 and MDM2 degrader programs KT-333 and KT-253 Phase 1 dose escalation studies ongoing with additional data expected in 2024 WATERTOWN, Mass., April 08, 2024 (
KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degrad
Kymera Therapeutics Inc (NASDAQ:KYMR) CFO Bruce Jacobs has sold 3,934 shares of the company's stock on March 4, 2024, according to a recent SEC filing.
Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) shareholders will have a reason to smile today, with the analysts making...
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: TD Cowen 44th Annual Healthcare Conference in Boston, MA on March 6 at 12:50 p.m. ET;Leerink Partners Global Biopharma Conference in Miami, FL on March 12 at 3:
Investors in Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) had a good week, as its shares rose 8.3% to close at US$41.84...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript February 22, 2024 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44. KYMR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the […]